Skip to main content

HomeResearchCompareARA-290 vs Testoluten

Peptide Comparison

ARA-290 vs Testoluten

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →
vs

Testoluten

testicular peptide bioregulator

LongevityResearch Only

1 providers listed

Full Testoluten profile →
Bottom line

ARA-290 carries stronger published evidence (RCT, 2 key studies) than Testoluten (Review, 1); both are research compounds.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Testoluten

Half-life

Which One Should You Choose?
Your goalBetter option
Stronger clinical evidenceARA-290
Further along in FDA reviewARA-290
Oral administration optionTestoluten
More provider options (17 vs 1)ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison
ARA-290
Testoluten
Mechanism Family
Longevity & Cellular
Longevity & Cellular
Half-life
~2 min (IV); ~10–20 min (SC)
FDA Status
investigational
unknown
Admin Routes
subcutaneous, intravenous
oral, subcutaneous
Availability
Research Only
Research Only
Providers
17 listed
1 listed
Avail. Notes
Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.
Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

Testoluten

Review · 1 key study · dated evidence base — most recent 2002
Research Citations

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas
neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Testoluten

Organ-specific peptide complex targeting testicular Leydig and Sertoli cells. Modulates steroidogenic gene expression to support testosterone biosynthesis pathways.

Research Areas
androgen supporttesticular functionhormonal balancelongevityfertility support
Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)
active erythrocytosis

No established clinical contraindications

Testoluten

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

ARA-290

$4.95/mg

$3.91$5.56 range

34 vendors

Testoluten

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Testoluten — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/ara-290/testoluten

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.